Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
